MDMA-assisted therapy for PTSD: where it stands after the 2024 FDA rejection

MDMA-assisted therapy for PTSD has been the most-watched psychedelic pipeline of the last decade. The August 2024 FDA rejection of Lykos Therapeutics' application was a setback, not an ending. With the April 2026 executive order, the timeline has reopened.

Here is a plain-English summary of what has happened, what is happening now, and what would have to go right for a US veteran or civilian PTSD patient to access MDMA-assisted therapy in a licensed clinic by 2027.

The short history

The Multidisciplinary Association for Psychedelic Studies (MAPS) ran two pivotal Phase 3 trials of MDMA-assisted therapy for PTSD between 2019 and 2023, with a treatment arm that paired three MDMA-assisted sessions with an extended psychotherapy protocol. The trials reported 67% of the treatment-arm participants no longer meeting PTSD criteria at the two-month follow-up, versus 32% in the placebo-plus-therapy arm. Effect sizes were large.

MAPS Public Benefit Corporation, which spun out to become Lykos Therapeutics, submitted a new drug application (NDA) based on those trials. An FDA advisory committee voted 9-2 against on efficacy in June 2024, citing concerns about trial blinding (MDMA is subjectively obvious, making traditional placebo blinding impossible), patient self-reporting bias, and ethical concerns raised about some trial sites. The FDA issued a Complete Response Letter in August 2024 declining the application.

The resubmission

Lykos resubmitted in late 2025 with additional analyses intended to address the blinding and bias concerns, including expectancy-controlled analyses and additional long-term follow-up data. That resubmission was working its way through a standard review cycle when the April 2026 executive order landed.

What the executive order changes

The April 2026 executive order directs the FDA to issue National Priority Vouchers (NPVs) to psychedelic drugs holding Breakthrough Therapy designation. Lykos' MDMA application holds that designation. An NPV compresses FDA review time from several months to a period of weeks.

If Lykos receives an NPV and the resubmission is deemed acceptable on re-review, first approval could land in late 2026. That is a significant compression from the previous baseline of mid-2027 at the earliest.

What approval would actually look like

MDMA-assisted therapy would almost certainly ship with a Risk Evaluation and Mitigation Strategy (REMS) program, similar to Spravato. Key operational details (not finalized until the label is issued): administration only at REMS-certified sites with trained therapist teams, monitored dosing sessions (typically 6-8 hours), requirement for preparatory and integration psychotherapy sessions, and strict patient screening for cardiovascular and psychiatric contraindications.

DEA rescheduling would be triggered by approval. Under the executive order language, that review begins at Phase 3 completion rather than at FDA approval, which shaves months off the access-to-clinic gap. Expected outcome: Schedule III or IV (prescription-controlled).

Where US patients can access MDMA-assisted therapy today

The honest answer for 2026 is: nowhere in the US, legally, outside a clinical trial. MDMA remains Schedule I. Ongoing Phase 3b and post-approval commitment trials at sites in CA, CO, NY, OR, and at several VA medical centers provide the only domestic access. Search ClinicalTrials.gov for 'MDMA PTSD' for current enrollment.

Patients and clinicians sometimes ask about overseas access (Australia legalized MDMA-assisted therapy for PTSD in July 2023 under tight prescriber authorization; a handful of Canadian programs operate under special access programs). Those are real but tightly controlled paths. Our directory does not list them because we only verify US-jurisdiction providers.

What this means for veterans specifically

The Department of Veterans Affairs is already running MDMA-assisted PTSD trials at multiple sites. The 2026 executive order directs HHS and FDA to coordinate trial-access expansion with the VA. For a post-9/11 veteran with a PTSD diagnosis, the fastest legitimate path to MDMA-assisted therapy right now is VA trial enrollment.

What to watch for in the next 90 days

FDA voucher issuance announcement (any or none). Lykos corporate updates on resubmission timeline. DEA pre-rescheduling notice-of-proposed-rulemaking if approval is imminent. We will keep this page updated as each lands.

Sources

FDA briefing document, Psychopharmacologic Drugs Advisory Committee Meeting, June 4, 2024. Lykos Therapeutics corporate communications, 2025-2026. The White House fact sheet, *Accelerating Medical Treatments for Serious Mental Illness*, April 18, 2026. Mitchell JM et al., *MDMA-assisted therapy for moderate to severe PTSD*, Nature Medicine (2023).